| DNA mismatch repair in cancer M Baretti, DT Le Pharmacology & therapeutics 189, 45-62, 2018 | 451 | 2018 |
| An analysis of genetic heterogeneity in untreated cancers JG Reiter, M Baretti, JM Gerold, AP Makohon-Moore, A Daud, ... Nature Reviews Cancer 19 (11), 639-650, 2019 | 180 | 2019 |
| Prognostic and predictive value of MET deregulation in non-small cell lung cancer G Finocchiaro, L Toschi, L Gianoncelli, M Baretti, A Santoro Annals of translational medicine 3 (6), 2015 | 148 | 2015 |
| Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer D Sefrioui, N Sarafan-Vasseur, L Beaussire, M Baretti, A Gangloff, ... Digestive and Liver Disease 47 (10), 884-890, 2015 | 78 | 2015 |
| The role of epigenetic therapies in colorectal cancer M Baretti, NS Azad Current problems in cancer 42 (6), 530-547, 2018 | 72 | 2018 |
| Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram F Pietrantonio, R Miceli, L Rimassa, S Lonardi, G Aprile, A Mennitto, ... Annals of Oncology 28 (3), 555-561, 2017 | 52 | 2017 |
| KRAS mutation in lung metastases from colorectal cancer: prognostic implications M Ghidini, N Personeni, S Bozzarelli, M Baretti, G Basso, P Bianchi, ... Cancer medicine 5 (2), 256-264, 2016 | 38 | 2016 |
| Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma M Simonelli, L Di Tommaso, M Baretti, A Santoro Immunotherapy 8 (12), 1363-1369, 2016 | 37 | 2016 |
| Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures K Mody, P Jain, SM El-Refai, NS Azad, DJ Zabransky, M Baretti, RT Shroff, ... JCO precision oncology 6, e2100510, 2022 | 34 | 2022 |
| Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice G Metro, B Ricciuti, R Chiari, M Baretti, L Falcinelli, D Giannarelli, A Sidoni, ... Lung Cancer 95, 82-87, 2016 | 27 | 2016 |
| Effect of comorbidities in stage II/III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single-center, observational study M Baretti, L Rimassa, N Personeni, L Giordano, MC Tronconi, T Pressiani, ... Clinical colorectal cancer 17 (3), e489-e498, 2018 | 21 | 2018 |
| The significance of ascites in patients with pancreatic ductal adenocarcinoma: a case-control study M Baretti, B Pulluri, HL Tsai, AL Blackford, CL Wolfgang, D Laheru, ... Pancreas 48 (4), 585-589, 2019 | 18 | 2019 |
| Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy M Baretti, M Yarchoan The Journal of Clinical Investigation 131 (16), 2021 | 12 | 2021 |
| Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection D Delitto, DJ Zabransky, F Chen, ED Thompson, JW Zimmerman, ... Oncoimmunology 10 (1), 2001159, 2021 | 12 | 2021 |
| Expanding the immunotherapy roadmap for hepatocellular carcinoma M Baretti, AK Kim, RA Anders Cancer cell 40 (3), 252-254, 2022 | 11 | 2022 |
| Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors KY Chen, A Popovic, D Hsiehchen, M Baretti, P Griffith, R Bista, ... Cancers 14 (21), 5347, 2022 | 10 | 2022 |
| Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities M Baretti, N Ahuja, NS Azad Annals of Pancreatic Cancer 2, 2019 | 9 | 2019 |
| Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? M Baretti, N Personeni, A Destro, A Santoro, L Rimassa Cancer Biology & Therapy 19 (8), 659-663, 2018 | 9 | 2018 |
| Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma SL Alden, M Lim, C Kao, D Shu, AG Singal, A Noonan, P Griffith, M Baretti, ... Cancer Research Communications 3 (7), 1312-1317, 2023 | 8 | 2023 |
| Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. M Baretti, JN Durham, R Walker, AL Mitcheltree, B Christmas, L Cope, ... Journal of Clinical Oncology 36 (15_suppl), TPS4151-TPS4151, 2018 | 8 | 2018 |
